Early benefits of empagliflozin in patients with type 2 diabetes with heart failure are not offset by increased adverse events: results from the EMPA-REG OUTCOME trial

Topics: 

Citation
Pellicori P et al. Eur Heart J 2019;40(Issue Supplement_1):ehz748.0952.